Longvida® was developed in collaboration with scientists , Dr. Sally Frautschy and Dr. Greg Cole at the University of California, Los Angeles (UCLA) and the supplements and food technology company Verdure Sciences®. On the 24th November 2015, The U.S Patent Office awarded the Indiana based company, patent number 9192644 for "Curcuminoid formulations having enhanced bio-availability".
Bio-availability is an area of major interest in Curcumin research. How long the Curcumin stays active in the human body is important for those taking the supplements and if bio-availability can be increased then the healthful benefits of the supplement can be increased as well.
The neuroscientists at UCLA developed the Longvida® Curcumin formulation so that it would pass through the blood brain barrier more easily. The blood brain barrier protects the brain from many drugs and supplements and this has long been a difficulty in the world of medicine. In tests, Longvida® has been found to be up to 285 times more powerful than standard 95% Curcumin and clinical data suggests that Longvida® helps with general health as well as brain health.
A 2014 study entitled 'Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population' was conducted using the Longvida® formulation. The study compared 400mg of Longvida® with a placebo. The study was also randomised and double blind which means the researchers didn't know which tablet was the placebo and which was the Curcumin. There were 60 healthy participants in the study who were aged between 60 - 85 years. Responses to the Curcumin and the placebo where measured at different intervals. After just 1 hour, researchers found that the Curcumin supplement improved results and the performance on tasks measuring working memory and attention. Furthermore, the Curcumin supplement improved lipid scores and was shown to significantly reduce total and LDL cholesterol.
Longvida® Associated With Significantly Reduced LDL Cholesterol
Other research studies indicate that Longvida® reduces inflammatory markers in the body as well as reducing oxidative stress. The formulation also has been shown to improve vascular health with the reduction of blood lipids (Triglycerides) and increases in nitric oxide which is the chemical that dilates arteries.
A further study undertaken by Dr. Robert DiSilvestro, Ph.D., Professor in the Department of Human Nutrition at Ohio State investigated the Longvida® Curcumin formulation. The study was a 30 day placebo controlled randomised study using a single 80mg supplement. The results from the study indicated that the beta-amyloid protein which is involved in Alzheimer's disease was actually lowered to a statistically significant level in the Curcumin group compared to the placebo group.
"These findings are consistent with previous data from several major universities suggesting that beta-amyloid can be bound by curcumin and may be cleared from the brain,” said Ebersole. “The clinical trial results are very exciting, and we anticipate more to follow"
Dr. Robert DiSilvestro, Ph.D